Here's your US review and approval news for the week in brief: Nektar didn't even wait around for the US Food and Drug Administration to make a final decision on the company's novel opioid oxycodegol, as it withdrew the new drug application almost immediately after an advisory committee voted unanimously against approval.
But as one novel product application left the FDA, many others piled into the agency. GlaxoSmithKline PLC's submitted its endometrial cancer candidate dostarlimab, while rolling submissions were initiated for bluebird bio Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?